Leja ML - Search Results

1

TBC1D24 emerges as an important contributor to progressive postlingual dominant hearing loss.

Oziębło D, Leja ML, Lazniewski M, Sarosiak A, Tacikowska G, Kochanek K, Plewczynski D, Skarżyński H, Ołdak M. Oziębło D, et al. Among authors: leja ml. Sci Rep. 2021 May 13;11(1):10300. doi: 10.1038/s41598-021-89645-y. Sci Rep. 2021. PMID: 33986365 Free PMC article.

2

First confirmatory study on PTPRQ as an autosomal dominant non-syndromic hearing loss gene.

Oziębło D, Sarosiak A, Leja ML, Budde BS, Tacikowska G, Di Donato N, Bolz HJ, Nürnberg P, Skarżyński H, Ołdak M. Oziębło D, et al. Among authors: leja ml. J Transl Med. 2019 Oct 26;17(1):351. doi: 10.1186/s12967-019-2099-5. J Transl Med. 2019. PMID: 31655630 Free PMC article.

3

Update on CD164 and LMX1A genes to strengthen their causative role in autosomal dominant hearing loss.

Oziębło D, Lee SY, Leja ML, Sarosiak A, Bałdyga N, Skarżyński H, Kim Y, Han JH, Yoo HS, Park MH, Choi BY, Ołdak M. Oziębło D, et al. Among authors: leja ml. Hum Genet. 2022 Apr;141(3-4):445-453. doi: 10.1007/s00439-022-02443-y. Epub 2022 Mar 7. Hum Genet. 2022. PMID: 35254497

4

Searching for the Molecular Basis of Partial Deafness.

Oziębło D, Bałdyga N, Leja ML, Skarżyński H, Ołdak M. Oziębło D, et al. Among authors: leja ml. Int J Mol Sci. 2022 May 27;23(11):6029. doi: 10.3390/ijms23116029. Int J Mol Sci. 2022. PMID: 35682719 Free PMC article.

5

Hearing Loss as the Main Clinical Presentation in NLRP3-Associated Autoinflammatory Disease.

Oziębło D, Leja ML, Jeznach A, Orzechowska M, Skirecki T, Więsik-Szewczyk E, Furmanek M, Bałdyga N, Skarżyński H, Ołdak M. Oziębło D, et al. Among authors: leja ml. Front Immunol. 2022 May 26;13:904632. doi: 10.3389/fimmu.2022.904632. eCollection 2022. Front Immunol. 2022. PMID: 35720340 Free PMC article.

6

The Genetic Background of Hearing Loss in Patients with EVA and Cochlear Malformation.

Bałdyga N, Oziębło D, Gan N, Furmanek M, Leja ML, Skarżyński H, Ołdak M. Bałdyga N, et al. Among authors: leja ml. Genes (Basel). 2023 Jan 28;14(2):335. doi: 10.3390/genes14020335. Genes (Basel). 2023. PMID: 36833263 Free PMC article.

7

Anticancer properties of 5Z-(4-fluorobenzylidene)-2-(4-hydroxyphenylamino)-thiazol-4-one.

Szychowski KA, Kaminskyy DV, Leja ML, Kryshchyshyn AP, Lesyk RB, Tobiasz J, Wnuk M, Pomianek T, Gmiński J. Szychowski KA, et al. Among authors: leja ml. Sci Rep. 2019 Jul 23;9(1):10609. doi: 10.1038/s41598-019-47177-6. Sci Rep. 2019. PMID: 31337851 Free PMC article.

8

Tetrabromobisphenol A (TBBPA)-stimulated reactive oxygen species (ROS) production in cell-free model using the 2',7'-dichlorodihydrofluorescein diacetate (H2DCFDA) assay-limitations of method.

Szychowski KA, Rybczyńska-Tkaczyk K, Leja ML, Wójtowicz AK, Gmiński J. Szychowski KA, et al. Among authors: leja ml. Environ Sci Pollut Res Int. 2016 Jun;23(12):12246-52. doi: 10.1007/s11356-016-6450-6. Epub 2016 Mar 15. Environ Sci Pollut Res Int. 2016. PMID: 26976009 Free PMC article.

9

Study of novel anticancer 4-thiazolidinone derivatives.

Szychowski KA, Leja ML, Kaminskyy DV, Binduga UE, Pinyazhko OR, Lesyk RB, Gmiński J. Szychowski KA, et al. Among authors: leja ml. Chem Biol Interact. 2017 Jan 25;262:46-56. doi: 10.1016/j.cbi.2016.12.008. Epub 2016 Dec 11. Chem Biol Interact. 2017. PMID: 27965178

10

Anticancer properties of 4-thiazolidinone derivatives depend on peroxisome proliferator-activated receptor gamma (PPARγ).

Szychowski KA, Leja ML, Kaminskyy DV, Kryshchyshyn AP, Binduga UE, Pinyazhko OR, Lesyk RB, Tobiasz J, Gmiński J. Szychowski KA, et al. Among authors: leja ml. Eur J Med Chem. 2017 Dec 1;141:162-168. doi: 10.1016/j.ejmech.2017.09.071. Epub 2017 Sep 30. Eur J Med Chem. 2017. PMID: 29031063

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

11 results

Search Page